文献速递脑血管病

口服抗凝与房颤或心衰患者卒中的比较荟萃分析

Association of Oral Anticoagulation With Stroke in Atrial Fibrillation or Heart Failure: A Comparative Meta-Analysis.
PubMed 文献 · Stroke · 2021-07-20

口服抗凝与全因卒中的关联在房颤(OR 0.51,95%CI 0.42–0.63)与HFrEF(OR 0.61,95%CI 0.47–0.79;I2=12.4%;P交互=0.31)中一致,心血管事件、死亡或出血关联无显著差异。

要点

  • 口服抗凝与房颤及HFrEF患者的全因卒中风险降低均相关,效应量相似。
  • HFrEF试验中全因死亡纳入主要结局的比例(95.2%)远高于房颤试验(0.38%)。
  • HFrEF对照组死亡率较高(19.0% vs 9.6%)但卒中率较低(3.1% vs 7.0%)。

核心结论

  • 口服抗凝与卒中风险及其他心血管结局的关联在房颤和HFrEF患者中相似。
  • HFrEF试验采用的主要结局与房颤试验不同,可能导致了口服抗凝相对疗效结论的差异。

主要发现

  • 口服抗凝与全因卒中的关联在房颤中OR 0.51(95%CI 0.42–0.63),在HFrEF中OR 0.61(95%CI 0.47–0.79);I2=12.4%,P交互=0.31。
  • HFrEF试验中全因死亡纳入主要结局的比例为95.2%,房颤试验为0.38%。
  • HFrEF对照组死亡率19.0%高于房颤的9.6%,卒中率3.1%低于房颤的7.0%。
  • 口服抗凝与心血管事件、死亡或出血的关联在两组人群间无统计学显著差异。

关键数值与推荐

  • 主要结局为全因卒中;次要结局包括缺血性卒中、出血性卒中、死亡、心肌梗死和大出血。
  • 通过估计所有试验间的I2及检验组间P交互评估治疗效应差异。

临床怎么用

  • 对于合并HFrEF且窦性心律的患者,口服抗凝可能带来与房颤患者相似的卒中风险降低。
  • 解读HFrEF抗凝证据时需注意试验主要结局构成的差异对结论的影响。

局限性

  • 原文未报告纳入试验的具体偏倚风险评价及异质性来源分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Atrial fibrillation and heart failure with reduced ejection fraction (HFrEF) are common sources of cardioembolism. While oral anticoagulation is strongly recommended for atrial fibrillation, there are marked variations in guideline recommendations for HFrEF due to uncertainty about net clinical benefit. This systematic review and meta-analysis evaluates the comparative association of oral anticoagulation with stroke and other cardiovascular risk in populations with atrial fibrillation or HFrEF in sinus rhythm and identify factors mediating different estimates of net clinical benefit. METHODS: PubMed and Embase were searched from database inception to November 20, 2019 for randomized clinical trials comparing oral anticoagulation to control. A random-effects meta-analysis was used to estimate a pooled treatment-effect overall and within atrial fibrillation and HFrEF trials. Differences in treatment effect were assessed by estimating I2 among all trials and testing the between-trial-population P-interaction. The primary outcome measure was all stroke. Secondary outcome measures were ischemic stroke, hemorrhagic stroke, mortality, myocardial infarction, and major hemorrhage. RESULTS: Twenty-one trials were eligible for inclusion, 15 (n=19 332) in atrial fibrillation (mean follow-up: 23.1 months), and 6 (n=9866) in HFrEF (mean follow-up: 23.9 months). There were differences in primary outcomes between trial populations, with all-cause mortality included for 95.2% of HFrEF trial population versus 0.38% for atrial fibrillation. Mortality was higher in controls groups of HFrEF populations (19.0% versus 9.6%) but rates of stroke lower (3.1% versus 7.0%) compared with atrial fibrillation. The association of oral anticoagulation with all stroke was consistent for atrial fibrillation (odds ratio, 0.51 [95% CI, 0.42–0.63]) and HFrEF (odds ratio, 0.61 [95% CI, 0.47–0.79]; I2=12.4%; P interaction=0.31). There were no statistically significant differences in the association of oral anticoagulation with cardiovascular events, mortality or bleeding between populations. CONCLUSIONS: The relative association of oral anticoagulation with stroke risk, and other cardiovascular outcomes, is similar for patients with atrial fibrillation and HFrEF. Differences in the primary outcomes employed by trials in HFrEF, compared with atrial fibrillation, may have contributed to differing conclusions of the relative efficacy of oral anticoagulation.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Reddin C, Judge C, Loughlin E, et al. Association of Oral Anticoagulation With Stroke in Atrial Fibrillation or Heart Failure: A Comparative Meta-Analysis. Stroke. 2021. PMID: 34281383. doi:10.1161/STROKEAHA.120.033910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。